PCSK9 expert opinions

Episodes 1-12 of 12

Identification of patients who will benefit is important after FOURIER
Identification of patients who will benefit is important after FOURIER
ACC.17
Identification of patients who will benefit is important after FOURIER
- Prof. Ulf Landmesser
PCSK9 outcome trials: The results put into perspective of other clinical developments
PCSK9 outcome trials: The results put into perspective of other clinical developments
ACC.17
PCSK9 outcome trials: The results put into perspective of other clinical developments
- Prof. Peter Sever
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
ACC.17
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
- Prof. Stephen J. Nicholls
The implications of PCSK9 outcome trials for GPs
The implications of PCSK9 outcome trials for GPs
ACC.17
The implications of PCSK9 outcome trials for GPs
- Prof. Richard Hobbs, MD
LDL lowering for CVD prevention: From hypothesis to axiom
LDL lowering for CVD prevention: From hypothesis to axiom
ACC.17
LDL lowering for CVD prevention: From hypothesis to axiom
- Prof. John JP Kastelein
No J-shaped curve for efficacy in PCSK9 outcome trials
No J-shaped curve for efficacy in PCSK9 outcome trials
ACC.17
No J-shaped curve for efficacy in PCSK9 outcome trials
- Prof Kausik Ray
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
ACC.17
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
- Prof. John Chapman
Changing therapeutic behaviour after FOURIER
Changing therapeutic behaviour after FOURIER
ACC.17
Changing therapeutic behaviour after FOURIER
- Prof. Wolfgang Koenig
Landmark study with PCSK9 inhibitor will change clinical practice
Landmark study with PCSK9 inhibitor will change clinical practice
ACC.17
Landmark study with PCSK9 inhibitor will change clinical practice
- Prof. Eric Bruckert
Lowering LDL-c for a longer period of time really matters
Lowering LDL-c for a longer period of time really matters
ACC.17
Lowering LDL-c for a longer period of time really matters
PCSK9 inhibition works, but you can’t force biology
PCSK9 inhibition works, but you can’t force biology
ACC.17
PCSK9 inhibition works, but you can’t force biology
- Prof. Wouter Jukema
PCSK9 inhibitors: From bench to bedside
PCSK9 inhibitors: From bench to bedside
ACC.17
PCSK9 inhibitors: From bench to bedside
- Prof. Gilles Lambert

Episodes 1-12 of 12

Title

Share on ReachMD